



Press Release

Radiopharm Theranostics entered into an exclusive license agreement with TRIMT

Carlton South, Australia / Radeberg, Germany, August 17th, 2021 – Radiopharm Theranostics, a company that develops diagnostic and therapeutic radiopharmaceuticals and aims to take them into clinical trials, today announced that TRIMT and Radiopharm Theranostics have entered into an exclusive license deal in the field of radiopharmaceuticals. The novel radioligands, also known as radiopharmaceuticals, were exclusively licensed to Radiopharm Theranostics in the important markets of the USA, China/Hong Kong, Japan and Australia and are based on technologies from the Technical University of Munich.

Subject to the license deal are innovative radioligands for imaging of different cancers, such as pancreatic carcinoma, cervical cancer, head and neck cancer and certain lung cancers as well as lung fibrosis.

The most common and aggressive form of pancreatic cancer, the ductal adenocarcinoma, is a disease with a very low average life expectation after diagnosis. Patients often experience no symptoms at early and even advanced and metastatic stages, so the cancer is usually discovered at late stages with no possibility of cure. Added to this, there are less effective treatment options available for pancreatic cancer in comparison to oncology products for other types of cancers, and this situation has not substantially improved during the last 40 years. The early and therewith timely diagnosis of pancreatic adenocarcinoma is still challenging, as its therapy. The outlicensed technology represents a groundbreaking new possibility to solve this challenges.

Radiopharm Theranostics, with scientific and development assistance from TRIMT, will exploit a cellular biomarker called $\alpha\beta6$ -integrin, which is found in high density on most pancreatic carcinoma cells, for sensitive localization of the nodules. The radioligand Ga-68-Trivehexin can track down pancreatic carcinoma by binding specifically even to small amounts of this biomarker. Thereafter, their position can be determined by highly sensitive detection systems, such as positron emission tomography (PET) scanners, facilitating the localization even of small tumors anywhere in the body. The information obtained with Ga-68-Trivehexin PET should help surgeons and oncologists to optimize their treatment, ideally facilitating complete surgical removal, or a better monitoring of the responsiveness to a chemotherapy. The next stage is to develop potent radiotherapeutics using the same mechanism of action, based on the promising diagnostic data already available. Radiopharm Theranostics plans to push the novel technologies towards clinical approval.

'We are thrilled to have TRIMT as a strong partner for the expansion of our clinical development portfolio. This opens up new opportunities for us to have a greater impact on supporting patients with life-threatening diseases', said Paul Hopper, Radiopharm Theranostics Executive Chairman. 'We are very pleased that TRIMT is helping to fill Radiopharm Theranostics' innovative product pipeline by providing access to the intellectual property of promising next-generation ligands in the field of radiopharmaceuticals, as well as scientific advice and development support for this powerful technology', added Dr. Jakub Simecek, TRIMT's Chief Executive Officer and Co-Founder.



Press Release

Notes to Editors

About Radiopharm Theranostics

Radiopharm Theranostics was founded in 2021 by Biotech industry doyen Paul A. Hopper. Similar to Chimeric, Viralytics and a number of other biotechs, Hopper has acquired the rights to what he believes are some of the most promising radiopharmaceutical diagnostic and therapeutic candidates from renowned universities. Hopper, who will serve as executive chairman, has recruited Cornell University's Professor David Mozeley as chief medical officer, radiopharmaceuticals expert Dr. Thom Tulip as chief technical officer and a CEO from a leading radiopharmaceutical company who is yet to be announced.

Radiopharm Theranostics already has five phase one clinical trials and three phase two trials underway, targeting a variety of cancers including breast, lung, head and neck, pancreatic and brain and is currently kicking off a pre-IPO raise ahead of a listing on the ASX (Australian Stock Exchange) in November.

Contact

Paul A. Hopper, Executive Chairman
ACN: 647877889 of Suite 1, Level 3
62 Lygon St.
Carlton South, VIC, 3053, Australia

About TRIMT

TRIMT GmbH was founded in early 2021 in Radeberg, the „Radiopharmacy Valley“ of Germany. The strategically advantageous position near Dresden (Saxony) was chosen due to the city's historical importance in radiopharmaceutical sciences. The location offers a cluster of excellent knowhow and collaboration opportunities - ranging from academia (TU Dresden) to established companies which are committed to chemistry and life science research, as well as to pharmaceutical manufacturing and production of radiopharmaceuticals.

Contact

Dr. Jakub Simecek, CEO
TRIMT GmbH
Carl-Eschebach-Str. 7
01454 Radeberg, Germany
Tel +49 (0) 3528 487 1940
www.trimt.de